Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837797 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
NCT01837797 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 129 participants.
The verdict
NCT01837797, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with Major Depressive Disorder (MDD)
Interventions
- DRUG Placebo
- DRUG Brexpiprazole 1 mg
- DRUG Brexpiprazole 3 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837797
The ClinicalTrials.gov registry entry for NCT01837797 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01837797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837797 about?
NCT01837797 is a clinical study titled "Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment". To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with Major Depressive Disorder (MDD)
What is the current status of trial NCT01837797?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01837797?
The interventions under investigation include: Placebo (DRUG), Brexpiprazole 1 mg (DRUG), Brexpiprazole 3 mg (DRUG).
Who is sponsoring clinical trial NCT01837797?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.